文献速递MDS 与骨髓增殖性肿瘤白血病

5-阿扎胞苷联合E-选择素拮抗剂uproleselan是增强骨髓增生异常和急性髓系白血病缓解的有效策略

Combining 5-azacitidine with the E-selectin antagonist uproleselan is an effective strategy to augment responses in myelodysplasia and acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2024-04-24

本文报道5-阿扎胞苷治疗后E-选择素配体合成相关基因启动子进一步低甲基化,FUT7和ST3GAL4上调,联合E-选择素拮抗剂uproleselan可逆转黏附并延长移植AML细胞小鼠的生存;高风险MDS和AML患者骨髓髓系细胞具有结合E-选择素的能力,且在5-阿扎胞苷无反应患者中更丰富。

要点

  • 5-阿扎胞苷使E-选择素配体合成基因启动子进一步低甲基化,上调FUT7和ST3GAL4。
  • 联合uproleselan可逆转E-选择素黏附并延长移植AML细胞小鼠的生存。
  • 高风险MDS和AML患者骨髓髓系细胞可结合E-选择素,且在5-阿扎胞苷无反应患者中更丰富。

核心结论

  • 数据为评估5-阿扎胞苷联合E-选择素拮抗剂uproleselan在该患者群体中的应用提供了有力依据。

研究设计与样本

  • 研究包含机制实验、小鼠移植实验和临床证据分析,探究5-阿扎胞苷与uproleselan联合策略。

主要发现

  • 5-阿扎胞苷治疗后,调控E-选择素配体sialyl Lewis X生物合成的启动子区域进一步低甲基化。
  • 上述基因产物上调,尤其是α(1,3)-岩藻糖基转移酶VII(FUT7)和α(2,3)-唾液酸转移酶IV(ST3GAL4),可能引起功能性E-选择素结合。
  • 与E-选择素拮抗剂uproleselan联用后,对E-选择素的黏附被逆转,移植AML细胞小鼠的生存期延长。
  • 临床证据显示高风险MDS和AML患者骨髓髓系细胞具有结合E-选择素的潜力,且这些细胞在5-阿扎胞苷无反应患者中更丰富。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The interaction of acute myeloid leukaemic (AML) blasts with the bone marrow (BM) microenvironment is a major determinant governing disease progression and resistance to treatment. The constitutive expression of E-selectin in the vascular compartment of BM, a key endothelial cell factor, directly mediates chemoresistance via E-selectin ligand/receptors. Despite the success of hypomethylating agent (HMA)-containing regimens to induce remissions in older AML patients, the development of primary or secondary resistance is common. We report that following treatment with 5-azacitidine, promoter regions regulating the biosynthesis of the E-selectin ligands, sialyl Lewis X, become further hypomethylated. The resultant upregulation of these gene products, in particular α(1,3)-fucosyltransferase VII (FUT7) and α(2,3)-sialyltransferase IV (ST3GAL4), likely causes functional E-selectin binding. When combined with the E-selectin antagonist uproleselan, the adhesion to E-selectin is reversed and the survival of mice transplanted with AML cells is prolonged. Finally, we present clinical evidence showing that BM myeloid cells from higher risk MDS and AML patients have the potential to bind E-selectin, and these cells are more abundant in 5-azacitidine-non-responsive patients. The collective data provide a strong rationale to evaluate 5-azacitidine in combination with the E-selectin antagonist, uproleselan, in this patient population.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Enjeti AK, Fogler WE, Smith TAG, et al. Combining 5-azacitidine with the E-selectin antagonist uproleselan is an effective strategy to augment responses in myelodysplasia and acute myeloid leukaemia. Br J Haematol. 2024. PMID: 38659295. doi:10.1111/bjh.19466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。